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Background: Gas vesicles are hollow, buoyant organelles bounded by a thin and extremely stable protein membrane.
They are coded by a cluster of gvp genes in the halophilic archaeon, Halobacterium sp. NRC-1. Using an expression
vector containing the entire gvp gene cluster, gas vesicle nanoparticles (GVNPs) have been successfully bioengineered
for antigen display by constructing gene fusions between the gvpC gene and coding sequences from bacterial and
viral pathogens.
Results: To improve and streamline the genetic system for bioengineering of GVNPs, we first constructed a strain of
Halobacterium sp. NRC-1 deleted solely for the gvpC gene. The deleted strain contained smaller, more spindle-shaped
nanoparticles observable by transmission electron microscopy, confirming a shape-determining role for GvpC in gas
vesicle biogenesis. Next, we constructed expression plasmids containing N-terminal coding portions or the complete
gvpC gene. After introducing the expression plasmids into the Halobacterium sp. NRC-1 ΔgvpC strain, GvpC protein and
variants were localized to the GVNPs by Western blotting analysis and their effects on increasing the size and shape of
nanoparticles established by electron microscopy. Finally, a synthetic gene coding for Gaussia princeps luciferase was
fused to the gvpC gene fragments on expression plasmids, resulting in an enzymatically active GvpC-luciferase fusion
protein bound to the buoyant nanoparticles from Halobacterium.
Conclusion: GvpC protein and its N-terminal fragments expressed from plasmid constructs complemented a
Halobacterium sp. NRC-1 ΔgvpC strain and bound to buoyant GVNPs. Fusion of the luciferase reporter gene from
Gaussia princeps to the gvpC gene derivatives in expression plasmids produced GVNPs with enzymatically active
luciferase bound. These results establish a significantly improved genetic system for displaying foreign proteins on
Halobacterium gas vesicles and extend the bioengineering potential of these novel nanoparticles to catalytically active
enzymes.
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Buoyant gas vesicles are prokaryotic organelles that are
widely distributed among bacterial and archaeal micro-
organisms and constitute protein nanoparticles (GVNPs)
that may be engineered for biotechnological applications
[1-3]. These organelles naturally promote flotation and in-
crease the availability of light and oxygen to many aquatic
microorganisms, especially those with photosynthetic or* Correspondence: sdassarma@som.umaryland.edu
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stated.phototrophic capabilities. Water is excluded from the in-
terior, a property that is thought to be a consequence of
the hydrophobicity of the interior surface of the protein-
aceous membrane. While the exact protein composition
of the membrane has been difficult to ascertain due to its
extreme stability against solubilization, production of
these structures is easily scaled-up and they are simple to
purify by hypotonic lysis of the host and concentrate by
flotation, enhancing their intrinsic value for biotechno-
logical applications [4,5].
Genetic analysis established the importance of a gene
cluster (gvpMLKJIHGFEDACNO) for gas vesicle forma-
tion in large plasmids of extremely halophilic Archaearal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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NRC-1, the gene cluster was found on a 191 kb plasmid,
pNRC100, with transcription of gvpACNO oriented
rightward, transcription of gvpDEFGHIJKLM oriented
leftward, and divergent promoters located in the 201 bp
gvpA-D intergenic region. Mutants constructed with
interruptions in each of the gvp genes by a kanamycin
cassette (κ) exhibited a partially or completely gas
vesicle-deficient phenotype, indicating that all of the gvp
genes are necessary for wild-type gas vesicle formation
[11]. This genetic system utilized the natural gas vesicle-
deficient mutant strain SD109, with a complete deletion
of the gvp gene cluster, and pFM104d, a large (18.9 kbp)
Halobacterium-E. coli shuttle plasmid containing the en-
tire 8.9 kbp gvp gene cluster [4,5,11-14].
The protein composition of gas vesicle nanoparticles
has been studied primarily by Western blotting analysis
using antisera directed against individual gvp gene prod-
ucts [15]. Initially, only GvpA and GvpC proteins were
found [8], but further analysis showed the presence of
five additional proteins, GvpF, GvpG, GvpJ, GvpL, and
GvpM [15]. GvpA, J, and M constitute a small family of
proteins (Pfam 741) likely involved in gas vesicle mem-
brane formation, while GvpF and L are coiled-coil pro-
teins (Pfam 6386) with self-associative properties thought
to be important for nucleation or growth of the nano-
particles [9,15]. Most of these proteins (GvpA, GvpC,Figure 1 Halobacterium sp. gas vesicle gene cluster and
thin-sections. (A) Genetic map of the gas vesicle gene cluster from
Halobacterium sp. NRC-1 pNRC100 is shown with genes transcribed
rightward colored red and genes transcribed leftward colored blue
[14]. The scale is noted above (divided into kilobase pairs) and the
positions of the gvpC deletion (Δ) and kappa insertion (κ) are indicated.
(B) and (C) Thin sections of Halobacterium sp. NRC-1 (B) and SD109
(pFM104gvpC::κ1) mutant (C) viewed by transmission electron
microscopy (bar, which is 325 nm long, applies to both B and C). Gas
vesicles are visible as empty oval or spindle-shaped regions. Shapes
observed reflect different planes of sectioning.GvpF, GvpJ, and GvpL) were also identified in a recent
proteomic study [16]. In genome sequencing studies,
genes corresponding to these same proteins were also
found in other gas vesicle-forming microbes [17]. An ex-
ception was the gvpC gene, which was reported only in
the haloarchaeal and cyanobacterial gas vesicle producers.
In Halobacterium sp. NRC-1, the gvpC gene encodes a
hydrophilic protein with a predicted molecular weight of
42,391 and a highly acidic pI of only 3.57 [8,9]. In this
haloarchaeon, the GvpC protein sequence contains 8
imperfect repeats and an extremely acidic stretch located
near the C-terminus. The slight similarity of the halo-
archaeal repeats to the repeats in the cyanobacteria sug-
gested that the GvpC proteins play similar roles in both
haloarchaea and cyanobacteria [18]. In the cyanobacter-
ium, Anabaena flos-aquae, GvpC has been shown to
serve a strengthening role in gas vesicles [19], while in
Halobacterium sp. NRC-1, insertion mutations in the
gvpC gene generated vesicles with altered shape and size
[11]. These findings suggested that GvpC proteins facili-
tate gas vesicles’ growth and enhance stability in strains
which produce them.
The potential value of GvpC protein for bioengineer-
ing floating GVNPs was established during mutagenesis
of the gvp gene cluster from Halobacterium sp. NRC-1.
A gvpC::κ insertion mutant was found to produce pri-
marily spindle-shaped gas vesicles with smaller than
wild-type size (Figure 1B & C) and excision of most of
the κ insert resulted in the production of vesicles with a
peptide fused to GvpC protein that was antigenically dis-
played and immunologically accessible on the surface
[7,11]. Further studies with SIV and chlamydial proteins
have shown that bioengineered GVNPs may be used for
antigen display and elicit both humoral and cellular re-
sponses in mice [4,5,20-22].
The genetic system currently in use for bioengineering
of gas vesicle nanoparticles is technically challenging
due to the large size and complexity of the gvp gene
cluster [7,8]. In order to facilitate bioengineering of
nanoparticles, we constructed a new Halobacterium sp.
NRC-1 derived host strain and a series of smaller, more
versatile plasmid expression vectors. The work docu-
mented in this report establishes a significantly im-
proved genetic system for expression of GvpC-fusion
proteins, including an active luciferase enzyme from
Gaussia princeps [23].
Results
Construction of a Halobacterium ΔgvpC strain and gvpC
expression vectors
In order to improve the genetic system for bioengineer-
ing of GVNPs [7,8], our first goal was the construction
of a gvpC deletion strain, via the ura3-based gene dele-
tion method for Halobacterium sp. NRC-1 [24,25].
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ing the first and last few codons of gvpC, were cloned into
the suicide vector, pBB400 [26], and the resulting plasmid,
pBB400ΔgvpC, was used to transform Halobacterium sp.
NRC-1Δura3. After selecting sequentially for integration
and excision (see Methods), the resulting Halobacterium
sp. NRC-1Δura3ΔgvpC deletion strain (referred hence-
forth as ΔgvpC deletion strain) (Figure 1A) showed a par-
tially gas vesicle-deficient phenotype with small, largely
spindle-shaped gas vesicles, similar to that reported for a
gvpC::κ insertion mutant (cf. Figure 1B and C).
To further develop the expression system and test for
complementation of the ΔgvpC strain, we constructed a
gvpC expression vector series (Figure 2). As the back-
bone, we used pMC2, an expression plasmid with the
high-level cold-inducible cspD2 promoter, and the ability
for replication and selection in both E. coli and Halo-
bacterium, recently constructed for investigation of a β-
galactosidase protein from a related haloarchaeon [27].
The β-galactosidase gene was excised and replaced with
an adapter containing a start codon, a hexahistidine-tag
(His-tag), and unique restriction sites for insertion of
the foreign genes, resulting in the plasmid pARK
(Table 1). A series of PCR amplified gvpC gene frag-
ments were then inserted into the unique AflII and AvrII
sites in the adapter region of pARK to construct the
pARK-C plasmid series containing various regions of
gvpC (Figure 2).Figure 2 Structure of pARK-C plasmid series used for expression
of gvpC fragments in Halobacterium sp. NRC-1 and ΔgvpC strains.
Location and transcriptional orientation of bla (pink), β-lactamase, for
ampicillin resistance; mev (black), HMG-CoA reductase for mevinolin
resistance; C1-C4, gvpC segments (blue), and rep (green), the
Halobacterium pGRB replicase gene are shown. Position of the
temperature-induced cspD2 promoter (labeled Pcs→), His-tag (red
box), and KpnI, NdeI, AflII, AvrII, and BamHI restriction sites are indicated.Engineering of the gvpC gene and expression of GvpC
fragments
To determine the effect of GvpC length on production
and bioengineering of GVNPs, we transformed each
member of the pARK-C plasmid series coding N-terminal
regions of GvpC into the ΔgvpC strain. pARK-C1 con-
tained 130 amino acids of GvpC, pARK-C2 contained 200
amino acids, pARK-C3 contained 280 amino acids, and
pARK-C4 plasmid and the wild-type strain contained the
complete 382 amino acid GvpC sequence (Figure 3).
When the phenotype of the ΔgvpC (pARK-C) transfor-
mants were compared to the parental ΔgvpC and Δura3
strains, increasing opacity resulting from increasing gas
vesicle content was observed in the following order:
ΔgvpC <ΔgvpC (pARK-C1) <Δgvp (pARK-C2) <ΔgvpC
(pARK-C3) ≈ΔgvpC (pARK-C4) ≈ Δura3 (Figure 4, cf.
panels A-F, respectively). These findings indicated lower
quantities of gas vesicle formation in strains expressing
smaller fragments of GvpC and higher quantities in strains
expressing larger GvpC fragments or the complete GvpC
protein.
To examine the morphology of GVNPs in ΔgvpC and
derivative ΔgvpC (pARK-C series) strains, we treated cells
to hypotonic conditions for lysis and purified nanoparti-
cles by centrifugally accelerated flotation (see Methods).
The vesicle preparations were spread for electron micros-
copy and stained with uranyl acetate, and observed as ei-
ther spindle-shaped or cylindrical-shaped structures. A
representative number of GVNPs were measured, con-
firming that nanoparticles from the parental ΔgvpC strain
were smaller and more spindle-shaped, as previously ob-
served for the gvpC::κ mutant, compared to the parental
Δura3 strain. The mean length and width of GVNPs
(blue and pink bars, respectively, in Figure 5) were pro-
portional to the size of gvpC gene fragment in pARK-C1,
C2, and C3 (386–432 nm lengths and 163–202 nm
widths), and were intermediate compared to the ΔgvpC
(344 and 158 nm, respectively) and Δura3 (458 and
256 nm, respectively) strains. Expression of larger GvpC
proteins generally resulted in production of longer and
wider gas vesicles.
Western blotting analysis was used to localize GvpC
protein and N-terminal fragments expressed from the
pARK-C plasmid series in ΔgvpC transformants. For this
analysis, confluent lawns of cells were grown and lysed
by hypotonic lysis. Gas vesicle nanoparticles were col-
lected after low-speed centrifugally accelerated flotation
and electrophoresed on SDS-polyacrylamide gels. After
transfer, rabbit antisera directed against either the His-tag
incorporated at the N-terminal region of GvpC (Figure 6),
or a synthetic GvpC peptide (data not shown), were used
in Western blotting analysis. The Western blots showed
GvpC proteins of expected sizes (N-terminal fragments
and full-length GvpC) localized to cell lysates (Figure 6,
Table 1 Strains and plasmids used in this study
Strain/plasmid Characteristics Source or reference
Halobacterium sp. strain
NRC-1
Sequenced wild-type strain Laboratory
collection [28]








Strain NRC-1Δura3 deleted for the gvpC gene This study
pFM104gvpC::κ1 Halobacterium-E. coli shuttle plasmid containing entire gvp gene cluster with κ insertion
in the gvpC gene
Laboratory
collection [11]
pBB400 Suicide plasmid capable of replication in E. coli but not Halobacterium,
containing the ura3 gene
Laboratory
collection [26]
pBB400ΔgvpC pBB400 plasmid containing gvpC gene-flanking regions for deletion construction This study




pARK Halobacterium sp. NRC-1 expression vector with cspD2 promoter and adapter containing
a start codon, His-tag, and restriction sites for insertion of the gvpC gene fragments
This study
pARK-C1 pARK derivative with gvpC gene C1 fragment This study
pARK-C2 pARK derivative with gvpC gene C2 fragment This study
pARK-C3 pARK derivative with gvpC gene C3 fragment This study
pARK-C4 pARK derivative with gvpC complete gene (C4) This study
pDRK Halobacterium sp. NRC-1 expression vector with gvpA promoter and adapter containing
a start codon, His-tag, and restriction sites used for insertion of the gvpC gene fragments
This study
pDRK-C1-L pDRK derivative containing gvpC gene C1 fragment fused to codon-optimized
Gaussia princeps luciferase gene
This study
pDRK-C2-L pDRK derivative containing gvpC gene C2 fragment fused to codon-optimized
Gaussia princeps luciferase gene
This study
pDRK-C3-L pDRK derivative containing gvpC gene C3 fragment fused to codon-optimized
Gaussia princeps luciferase gene
This study
pDRK-C4-L pDRK derivative containing gvpC complete gene (C4) fused to codon-optimized
Gaussia princeps luciferase gene
This study
Figure 3 GvpC protein sequence and engineering sites. The amino acid sequence of GvpC of Halobacterium sp. NRC-1 is shown with
conserved residues (vertical bars) in the eight imperfect repeats. The GvpC segments used in this study are labeled C1, C2, C3 and C4 at the
C-terminal end. Τhe position of the κ insertion in the gvpC mutant is labeled ‘κ’.
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Figure 4 Phenotype of Halobacterium sp. NRC-1Δura3ΔgvpC
and derivative strains containing gvpC expression plasmids
with fragments of varying lengths. Increasing opacity (from orange
to pink color) indicates higher levels of GVNPs produced in cells.
Cultures of the following strains are shown spotted on CM+ plates:
A: Halobacterium sp. NRC-1Δura3ΔgvpC, B: Halobacterium sp. NRC-
1Δura3ΔgvpC (pARK-C1), C: Halobacterium sp. NRC-1Δura3ΔgvpC
(pARK-C2), D: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C3),
E: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C4), and
F: Halobacterium sp. NRC-1Δura3.
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(Figure 6, arrows, lanes 7–10). As previously reported for
the GvpC protein, the apparent protein sizes were signifi-
cantly larger than predicted from molecular weight stan-
dards, due to its high acidity [8,15].
Luciferase expression and display on gas vesicles
In order to determine whether GVNPs produced in the
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Figure 5 Gas vesicle nanoparticle dimensions in Halobacterium
sp. NRC-1Δura3 and ΔgvpC derivative strains containing gvpC
expression plasmids. Average dimensions for nanoparticle length
(blue) and width (pink) are shown in nanometers (vertical axis), and
standard deviation shown with error bars. A: Halobacterium sp.
NRC-1Δura3ΔgvpC, B: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C1),
C: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C2), D: Halobacterium
sp. NRC-1Δura3ΔgvpC (pARK-C3), E: Halobacterium sp. NRC-1Δura3.proteins, we expressed a synthetic luciferase gene from
the marine copepod Gaussia princeps fused to the gvpC
gene or its N-terminal fragments [23]. Codons in the
synthetic luciferase gene were optimized to reflect usage
in Halobacterium sp. NRC-1 [29] and the gene was
inserted into the pARK-C plasmid series via an engi-
neered AfeI site to produce GvpC-luciferase gene fusions
(Figure 7). In order to increase the level of expression,
the cspD2 promoter was replaced by the stronger gvpA
promoter [9,10,30], recently used to bioengineer ex-
tremely radiation resistant derivatives of Halobacterium
sp. NRC-1 [31], via the KpnI and NdeI sites (see also
Figure 2 and Table 1). Each member of the constructed
plasmid series, named pDRK-C1-L to pDRK-C4-L (Figure 7),
was then transformed into both wild-type NRC-1 and
ΔgvpC strains, transformants were grown as lawns on agar
plates and lysed hypotonically, and the GVNPs purified by
centrifugally accelerated flotation. To determine whether
luciferase was bound to the floating GVNPs, chemilumin-
escence activity was compared between the subnatant and
the floating GVNP fraction. The results showed that
GvpC-luciferase fusion protein was bound to GVNPs and
was enzymatically active (Figure 8). Higher levels of activ-
ity were observed for the fusion proteins with longer
GvpC-fragments or the entire GvpC protein (C3 and C4)
compared to the shorter fragments (C1 and C2) (cf. C and
D versus A and B in Figure 8).
Interestingly, when members of the pDRK-C-L plas-
mid series were transformed into Halobacterium sp.
NRC-1, which contains a wild-type gvpC gene, nanopar-
ticles containing engineered GvpC-luciferase proteins
were also detectable by luciferase activity (Figure 8, pink
bars) and Western blotting assays (data not shown). Al-
though higher levels of luciferase activity were observed
bound to floating gas vesicle nanoparticles in the ΔgvpC
(pDRK-C1-L to C4-L) strains compared to the NRC-1
(pDRK-C1-L to C4-L) strains, luciferase activity was
clearly measurable in nanoparticles in the transformed
wild-type strain (Figure 8). Moreover, the wild-type
GvpC protein was also detected bound to GVNPs in the
NRC-1 (pDRK-C1-L to C4-L) strains (data not shown),
indicating that two different GvpC forms may be simul-
taneously bound to the nanoparticles. These results
extend the possible biotechnological uses of GVNPs
to other applications requiring nanoparticle-bound en-
zymes and multivalency.
Discussion
We have established an improved genetic system for bio-
engineering of GVNPs in the model halophilic archaeon,
Halobacterium sp. NRC-1. A strain deleted for the gvpC
gene and plasmid vectors containing highly active pro-
moters for producing GvpC-fusion proteins were con-
structed. The system was tested by expressing the entire
Figure 6 Western blotting analysis of Halobacterium sp. NRC-1Δura3ΔgvpC and derivative strains containing gvpC expression plasmids.
Cell lysates (lanes 1–5) or gas vesicles (lanes 6–10) were electrophoresed on a 12% polyacrylamide-SDS gel, transferred to PVDF membrane, and
probed with His-tag antibody followed by secondary antibody-alkaline phosphatase conjugate. Lanes 1 & 6: Halobacterium sp. NRC-1Δura3ΔgvpC,
Lanes 2 & 7: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C1), Lanes 3 & 8: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C2), Lanes 4 & 9: Halobacterium
sp. NRC-1Δura3ΔgvpC (pARK-C3), Lanes 5 & 10: Halobacterium sp. NRC-1Δura3ΔgvpC (pARK-C4).
25
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and GvpC-luciferase fusion proteins, all of which bound
to the buoyant nanoparticles. The improved genetic en-
gineering system provides the opportunity for insertion
of multiple foreign sequences and the potential for
production of GVNPs displaying multiple antigens. The
work reported here represents a significant step forward
in demonstrating the bioengineering capabilities of
GVNPs, including their application to antigen display
and vaccine development.
The current work has capitalized on the Halobacterium
sp. NRC-1 genetic system and recently constructed ex-
pression plasmids [25-27,31]. These biotechnological tools
have been used to overexpress, purify, and characterize a
polyextremophilic β-galactosidase enzyme from an Ant-
arctic haloarchaeon, and bioengineer resistance of halo-
archaeal cells to ionizing radiation by overexpression of a
mammalian-type RPA protein [27,31]. The constructedFigure 7 Partial map of pDRK-C-L plasmid series used for
expression of gvpC-luciferase fusion genes in Halobacterium sp.
NRC-1 and ΔgvpC strains. The upper map (pARK-C series) displays
the KpnI-BamHI region of the pARK-C series plasmids, with the cspD2
promoter labeled Pcs, His-tag shown as red box, and gvpC gene
(with C1, C2, C3, and C4 regions marked) shown as blue arrow. The
four lower maps (labeled pDRK-C1-L to C4-L) show the KpnI-BamHI
regions of pDRK-C-L plasmid series containing the gvpA promoter
(labeled Pgv), His-tag (red box), C1, C2, C3, and C4 regions of gvpC
(blue boxes), and codon optimized Gaussia princeps luciferase gene
(yellow arrow). The corresponding sites of KpnI, NdeI, and BamHI
cleavage are indicated, while the AfeI sites at the GvpC-luciferase
gene boundaries are not shown.expression plasmids (pARK and pDRK) contain the high-
copy number Halobacterium sp. pGRB miniplasmid for
replication and the mevinolin resistance gene for selection
in haloarchaea, as well as the plasmid pUC18 vector for
replication and selection in the E. coli host. The pARK ex-
pression plasmids contain the cspD2 promoter while the
pDRK expression plasmids contain the gvpA promoter.
Both of these promoters were reported to drive expression
of genes inducible under cold temperatures [30]. The
pARK and pDRK plasmids were tailored for expression of
GvpC fusion proteins and represent convenient vectors
for production of bioengineered GVNPs.
Our GVNP-bioengineering and expression system ex-
ploits genetic properties of the Halobacterium sp. NRC-
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Figure 8 Luciferase activity in purified GVNPs from
Halobacterium sp. NRC-1Δura3ΔgvpC and Halobacterium sp.
NRC-1 strains containing gvpC and luciferase expression
plasmids. Percent luciferase activity, chemiluminescence activity
detected in gas vesicles compared to the total activity observed in
cell lysates, is plotted on vertical axis for pDRK-C-L plasmid series.
Values plotted are the average of experiments performed in triplicate,
and standard deviation shown with error bars. A: pDRK-C1-L, B: pDRK-
C2-L, C: pDRK-C3-L, D: pDRK-C4-L in either Halobacterium sp.
NRC-1Δura3ΔgvpC (blue), or in wild-type Halobacterium sp. NRC-1
(pink) strain.
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plasmid [8,9]. The ΔgvpC deletion strain, constructed
using our ura3-deletion method [24,25], contained gas
vesicles with smaller, more spindle-shaped vesicles ob-
servable by transmission electron microscopy. This find-
ing is consistent with earlier observations suggesting a
key role for GvpC protein in shape determination of gas
vesicles in haloarchaea [11,32]. As larger GvpC protein
variants were supplied via expression plasmids, we ob-
served generally longer and wider vesicles, suggesting
that the nanoparticles were increasingly strengthened.
Similar results were also obtained for some cyanobac-
teria, where a strengthening role for the GvpC protein
was reported [19,33]. In one study, A. flos-aquae GvpC
protein produced in E. coli could bind and strengthen
the structures after native GvpC protein had been re-
moved by urea treatment. GvpC genes have been
reported in most if not all gas vesicle-containing halo-
archaea and cyanobacteria, indicating that the protein
may serve similar functions in these two groups of
aquatic microorganisms. However, gvpC is reportedly
absent in other gvp gene-containing species, a finding
suggesting that it may not be absolutely essential for bio-
synthesis of gas vesicles [1,15].
An interesting feature of the GvpC protein is the pres-
ence of internal repeats (8 in Halobacterium sp. NRC-1)
[9]. Our results show that even a small subset of these
repeats in truncated variants of GvpC proteins is suffi-
cient to permit binding to GVNPs. In the pARK-C1 con-
struct, only 3 copies are present, while in pARK-C2,
there are 5. Both of these plasmids produced proteins
that bound to the vesicles. The longer GvpC variants
produced from pARK-C3 and C4 (7 or 8 repeat copies,
respectively), complemented production of the nano-
particles considerably better than the smaller GvpC pro-
teins, based on both colony phenotype and vesicle
morphology. Similar conclusions were previously re-
ported for A. flos-aquae GvpC protein variants contain-
ing three or four repeats (out of 5 in the full-length
protein) in in vitro experiments [34]. In this cyanobac-
terial system, GvpC depleted vesicles had their strength
better restored with proteins containing larger numbers
of repeats. In Halobacterium sp. NRC-1, the presence of
a highly acidic C-terminal region suggests a further role
for this feature in stabilizing gas vesicles, likely reflecting
the high salinity found in the cytoplasm.
We used a synthetic Gaussia princeps luciferase gene
to further assess the binding of GvpC fusion proteins to
gas vesicles. Initially, we found that the luciferase protein
was active when produced in Halobacterium via expres-
sion vectors alone (our unpublished results) or as a fu-
sion with the GvpC fragments or full-length protein,
demonstrating that the marine enzyme was capable of
adopting an active structure even after exposure to thehypersaline cytoplasm of Halobacterium. Further investi-
gation showed that the GvpC-luciferase fusion proteins
were bound to buoyant gas vesicles, confirming that the
enzyme is likely displayed on the surface of nanoparti-
cles. Although antigenic proteins and protein fragments
have been previously found to be displayed on gas vesi-
cles, these findings now show that an enzyme may also
decorate the nanoparticles while retaining its catalytic
activity. Moreover, when two different gvpC genes (wild-
type and shortened/fused to luciferase) were present, we
found that both GvpC forms were bound to the nanopar-
ticles. These results extend the possible biotechnological
uses of GVNPs to applications requiring multivalency.
All together, our results provide improved genetic and
plasmid resources for engineering of GVNPs for bio-
technological applications. The original system described
required the incorporation of target genes into a large
plasmid containing the entire gvp gene cluster, pFM104d,
and a natural mutant strain deleted for the gene cluster,
SD109 [7,8,11-13,35]. The newly described system utilizes
the much smaller and more versatile plasmid series, pARK
and pDRK, containing a relatively small portion of the gvp
gene region. The new system allows more facile cloning of
genes of interest into the smaller expression vectors and
replacement of only a single deleted gene (ΔgvpC) in the
gvp gene cluster. These features will greatly facilitate ex-
pression of foreign proteins in GVNPs, including antigenic
proteins from pathogenic microorganisms for vaccine
development.
Conclusions
Gas vesicle nanoparticles (GVNPs) in the halophilic
archaeon, Halobacterium sp. NRC-1, are successfully be-
ing used for antigen display and vaccine development.
The genetic tools for bioengineering GVNPs have now
been greatly improved through construction of a Halo-
bacterium strain deleted for the gvpC gene and smaller
plasmids for expression of foreign proteins fused to
GvpC proteins. The utility of the improved system has
been demonstrated by expression of an active Gaussia
princeps luciferase enzyme fused to GvpC and bound to
buoyant gas vesicles. These results establish a signifi-
cantly improved genetic system for displaying foreign
proteins on GVNPs and extend the bioengineering po-
tential of these novel nanoparticles to catalytically active
enzymes.
Methods
Culturing and nanoparticle preparation
Halobacterium strains used for this study (Table 1) in-
cluded NRC-1, the wild-type (ATCC 700922/JCM11081)
[28], SD109, with deletion of the entire gas vesicle gene
cluster [13,35], SD109 (pFM104gvpC::κ1), with insertions
of a kanamycin (κ) cassette in the gvpC gene [11],
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1Δura3ΔgvpC constructed in this study. These strains
were grown in CM+ media, as previously described, with
the addition of mevinolin (20 μg/ml) (generously pro-
vided by Merck, Sharp, and Dohme, Rahway, NJ) when
transformed with expression plasmids [26,27].
For preparation of nanoparticles, lawns of Halobacter-
ium cells were collected by washing with 5 ml of PBS so-
lution [137 mM NaCl, 2.7 mM KCl, 10 mM sodium
phosphate dibasic, and 2 mM potassium phosphate
monobasic (pH 7.4)] containing 1.0 mM MgSO4. Ten
μg/ml of DNase I (Roche Diagnostics, Indianapolis, IN)
was added and the cell lysate suspension was incubated
for 3 hours at 37°C. Lysates were centrifuged at 60 × g
overnight in a swinging bucket rotor using a Jouan
CR412 centrifuge (Thermo Scientific, Rockford, IL) to
accelerate flotation of the gas-filled nanoparticles. Next,
intact buoyant nanoparticles were carefully collected into
a clean tube and resuspended in PBS solution, floated by
overnight centrifugation, as above, and re-collected. The
flotation procedure described above was repeated until a
milky white suspension of GVNPs was obtained.
For preparation of whole cell extracts, liquid cultures
of Halobacterium strains were grown in an illuminated
Innova 44 incubator shaker (New Brunswick Scientific,
Enfield, CT) at 42°C with shaking at 220 rpm. Ten ml
cultures (OD 1.2 at 600 nm) were harvested by centrifu-

















Universal F 20mer GTTGTAAAACGACGGCCAGT
Universal R 20mer CACAGGAAACAGCTATGACC
Luci Int R GTGGCTGAGGCAGATGAGGCcentrifuge. Pellets were resuspended in 0.5 ml of sterile
distilled water containing freshly prepared 1 mM phenyl-
methylsulfonyl fluoride (Sigma Corporation, St. Louis,
MO), 10 μg/ml DNase I was added, and the lysates incu-
bated at 37°C for 30 minutes and dialyzed against 4 liters
of distilled water at 4°C overnight. Protein concentrations
were determined by the Bradford dye (Bio-Rad Laborator-
ies, Hercules, CA) binding method [36] using bovine
serum albumin (BSA, Sigma Corporation) as a standard.
Construction of Halobacterium ΔgvpC strain
Approximately 500 bp regions flanking gvpC were amp-
lified by crossover PCR (using primers shown in Table 2).
The resulting amplified crossover PCR fragment was
cloned using flanking HindIII sites incorporated in the
primers, into the HindIII site of pBB400 (Table 1) [26].
The resulting plasmid, pBB400ΔgvpC, deleted 359/382 co-
dons of the internal portion of the gvpC gene, but retained
the first and last seven codons of gvpC as well as seven
additional codons in the crossover region. The final con-
struct was sequenced to verify correctness of the inserted
PCR fragment and transformed into Halobacterium sp.
NRC-1Δura3 using the PEG-EDTA method [37].
pBB400ΔgvpC transformants were selected by plating
on CM+ media lacking uracil (HURA), colonies picked
and grown in liquid HURA media, and genomic DNA
extracted, as previously described [26,37]. Integrant can-








CTACCTAGGAGCGCTTGAGGATCCATC His-tag adapter for gvpC
and antigen fusion expression
plasmid constructionGTGGTGGTGGTGGTGCATATGGAGACG
Sequencing of promoters





of luciferase gene orientation
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on CM+ plates containing 250 μg/ml 5-fluorouracil (5-
FOA) (Toronto Research Chemicals, North York,
Canada). Excisant colonies were picked and grown in li-
quid CM+ media containing 5-FOA, genomic DNA was
extracted, and PCR reactions were used to screen for
knockout mutants using primers flanking the gvpC gene
(Table 2).
Construction of the pARK and pDRK expression plasmids
For construction of the Halobacterium sp. pARK and
pDRK expression plasmids, pMC2 expression plasmid
was used as the backbone [26,27]. The β-galactosidase
gene was excised and replaced with an adapter (see
Table 2) containing a start codon, hexahistidine-tag
(His-tag), and AflII, AvrII, and AfeI restriction sites. The
C1-C4 GvpC fragments were PCR amplified and inserted
via the AflII and AvrII sites, and the synthetic Gaussia
princeps luciferase gene (LifeTechnologies, Grand Island,
NY) was inserted via the AfeI site [23]. The promoter re-
gion was replaced via the KpnI and NdeI sites. The con-
structs were validated by DNA sequencing.
Electron microscopy
For thin-sectioning, cells were fixed in 3% glutaraldehyde-
20% NaCl, postfixed in 2% OsO4-20% NaCl for 4 hours,
rinsed with 20% NaCl, stained with 5% uranyl acetate in
20% NaCl-20% acetone for 1 hour, and then dehydrated
by immersion in a series of isotonic acetone solutions.
Samples were then embedded in Spurr medium which
was polymerized at 70°C for 8 hours [38]. Thin sections of
600 Å (60 nm) were examined on copper grids stained
with lead [39].
For negative staining, purified nanoparticles were
adsorbed to glow discharged 400 mesh carbon coated
parlodion copper grids for 30 seconds. Grids were then
rinsed in distilled deionized water, 3 times for 30 seconds
each. Nanoparticles were negatively stained two times
for 30 seconds each in 1% uranyl acetate with 0.04%
tylose. Grids were blot dried with Whatman #1 filter
paper and samples imaged on a Hitachi 7600 TEM at
80 kV. Images were captured with an AMT CCD (1 K ×
1 K) camera at 8,000× and 30,000× magnifications. Fifty
representative gas vesicle nanoparticles from each strain
were measured and average values and standard devia-
tions calculated.
Western blotting analysis
The methods used were similar to those previously de-
scribed [15]. Briefly, cell lysates containing 50 μg of pro-
tein or purified gas vesicle nanoparticle preparations
containing 2 μg of protein were electrophoresed on 12%
polyacrylamide-SDS gels, for 90 minutes at 100 volts using
a Bio-Rad vertical gel electrophoresis unit. Proteins weretransferred to 0.45 μm Immobilon-P polyvinylidene di-
fluoride (PVDF) membranes (Millipore Corp., Boston,
MA) for 1 hour at 100 volts using a Bio-Rad gel blotter.
The membranes were washed twice for 5 minutes with
TBS buffer [20 mM Tris–HCl (pH 7.6), 137 mM NaCl],
blocked for 1 hour with 5% BSA in TBS buffer, incubated
overnight at 4°C with affinity column purified rabbit GvpC
antibodies (Thermo Scientific) diluted 1:500 [15] or rabbit
anti-His-tag antibody (Cell Signaling Technology, Beverly,
MA) diluted 1:750. Membranes were then washed 5 times
each for 5 minutes with TBS buffer containing 0.1%
Tween 20, and incubated with goat anti-rabbit secondary
antibodies labeled with alkaline phosphatase (Sigma Cor-
poration), diluted (1:2500) in a solution containing 5%
BSA in TBS buffer. For detection of the protein bands, the
membrane was incubated in 1-Step NBT/BCIP Substrate
(Thermo Scientific) according to the manufacturer’s
specification.
Luciferase activity
Whole cell lysates or purified gas vesicle nanoparticles pre-
pared as described above were assayed for Gaussia princeps
luciferase activity using the Glow Assay system (Thermo
Scientific) according to the manufacturer’s specification.
Assays were conducted in 96-well plates using a Spectra-
Max M5 luminometer (Molecular Devices, Sunnyvale, CA).
Induction was calculated in relative light units of the
treated sample/average relative light units of the untreated
samples.
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